Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Food and Drug Administration - June 30, 2006
Richard Klein, Kimberly Struble
The recommended regimen for the lamivudine-zidovudine-nevirapine tablet is one pill twice a day following an initial two week treatment with the individual components taken individually. Each ingredient of this generic tablet is currently approved to treat HIV-1 infected adults in combination with other antiretroviral agents. The safety and effectiveness of the combination of lamivudine-zidovudine-nevirapine in lowering the viral load and increasing the CD4+ cell has been demonstrated in previously conducted adequate and well controlled studies of the individual ingredients being used together for treatment.
The labeling of the combination drug includes a medication guide and a boxed warning that the drug's use can cause liver failure, severe rash, and lactic acidosis (buildup of an acid in the blood).
Under the PEPFAR program, the FDA may grant a tentative approval if it concludes that a drug product has met all of the required clinical safety and efficacy and manufacturing quality standards for marketing in the United States. However, because of existing patents and/or exclusivity rights protecting the individual innovator products, the fixed dose combination product cannot be sold on the United States at this time.
Richard Klein, Office of Special Health Issues
Food and Drug Administration
Kimberly Struble, Division of Antiviral Products
Food and Drug Administration
060630
FD060607
SOURCE: Food and Drug Administration (FDA).
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, the Elton John AIDS Foundation, National Library of Medicine, and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .